Third Teleconference R&I DGs on R&I action on COVID-19

15 April 2020

15.00 – 17.00 hrs

Annotated Agenda

15.00 – 15.05 Welcome by Jean-Eric Paquet, Director-General DG R&I

15.05 – 15.30 ERAvsCorona Action Plan

*The purpose of this agenda point is to discuss the implementation of the first 10 priority ERAvsCorona actions and to identify additional actions. Background papers for this agenda point are a note on how to take the first 10 priority actions forward from DG R&I as well as a note summarizing suggestions for possible additional actions and a first reaction from DG R&I on those:*

****

*Background documents on existing ERAvsCorona actions:*

************

15.30 – 16.45 Vaccines, treatment and diagnostics: development and manufacturing

*The purpose of this agenda point is to discuss the next steps on vaccine, treatment and diagnostics development and manufacturing, following the exchange of views on 31 March. Four background papers on vaccines, clinical trials, treatment and diagnostics have been prepared for this agenda point:*

********

*Question for discussion:*

* *Do you agree with a consolidated EU approach as stepping stone for the EU pledging conference?*
* *How do you see your national contribution to this pledging event?*

16.45 – 17.00 AOB, Discussion on next steps and conclusions

*NB:* *Member States are kindly requested to send their input in writing beforehand and to focus on key messages in their intervention during the videoconference.*

*\*\*\**